Adding Tiragolumab to Atezolizumab Plus Chemotherapy Does Not Improve Outcomes in Small-Cell Lung Cancer - Cancer Network
6/5/2022 12:00:00 AM2 years 10 months ago
by Brielle Benyon
by Brielle Benyon
The addition of tiragolumab to atezolizumab plus carboplatin and etoposide did not yield improved overall survival or progression-free survival rates in patients with extensive-stage small-cell lung cancer.
Adding tiragolumab to atezolizumab (Tecentriq) plus carboplatin and etoposide (CE) did not result in improved outcomes compared with atezolizumab plus CE in patients with untreated extensive-stage sm… [+3728 chars]
full article...